Methylated Nucleotide-Based Proteolysis-Targeting Chimera Enables Targeted Degradation of Methyl-CpG-Binding Protein...

Area of Science:

• Epigenetics
• Molecular Biology
• Cancer Therapeutics

Background:

• Methyl-CpG-binding protein 2 (MeCP2) is implicated in neurological disorders and increasingly recognized for its oncogenic role in cancer.
• Targeting MeCP2 for cancer therapy is challenging due to its function as an epigenetic regulator.
• Developing novel therapeutic strategies to degrade oncoproteins like MeCP2 is crucial.

Purpose of the Study:

• To introduce a novel methylated nucleotide-based chimera, methyl-proteolysis-targeting chimera (methyl-PROTAC), for targeted degradation of MeCP2.
• To evaluate the antiproliferative and cytotoxic effects of methyl-PROTAC in cancer cells overexpressing MeCP2.
• To explore the potential of methyl-PROTAC as a therapeutic strategy for cancers driven by MeCP2.

Main Methods:

• Design and synthesis of methyl-PROTACs incorporating methylated cytosine into an oligodeoxynucleotide.
• Assessment of MeCP2 recruitment and degradation mediated by methyl-PROTAC.
• Evaluation of von Hippel-Lindau (VHL) and proteasome dependency for methyl-PROTAC activity.
• Analysis of antiproliferative effects and induction of apoptosis in cancer cell lines.

Main Results:

• Methyl-PROTAC successfully recruits and facilitates the targeted degradation of MeCP2.
• Degradation of MeCP2 by methyl-PROTAC occurs in a VHL- and proteasome-dependent manner.
• Methyl-PROTAC exhibits selective cytotoxicity against cancer cells with high MeCP2 expression.
• Methyl-PROTAC-induced MeCP2 degradation triggers apoptosis in cancer cells.

Conclusions:

• Methyl-PROTAC represents an innovative approach for targeted protein degradation of epigenetic factors.
• This strategy demonstrates therapeutic potential for eliminating cancer cells dependent on MeCP2 overexpression.
• Methyl-PROTAC offers a promising avenue for developing novel PROTAC-based therapeutics against previously undruggable targets.